Doxorubicin enhanced both PTPRZ1 and PTN expression in the triple-negative breast cancer MDA-MB-231 and MDA-MB-453 cells, promoting cell proliferation and inhibiting apoptosis through PTPRZ1-dependent activation of NFκΒ [15]. The gene discussed is PTN; the disease is triple-negative breast carcinoma.